专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130084333A1 ABUSE RESISTANT ORAL DOSAGE FORMS 有权
标题翻译：滥用耐药性口服剂型
公开(公告)号：US20130084333A1
公开(公告)日：2013-04-04
申请号：US13379481
申请日：2010-06-25
申请人： Christopher C. Dick , David F. Erkoboni , Charanjit R. Behl , Gary Bubb
发明人： Christopher C. Dick , David F. Erkoboni , Charanjit R. Behl , Gary Bubb
IPC分类号： A61K9/28
CPC分类号： A61K9/28 , A61K9/2027 , A61K9/2095 , A61K9/2846 , A61K9/2866 , A61K9/2873 , A61K9/2893 , A61K31/485
摘要： Aspects of the present invention are directed to abuse resistant oral dosage forms comprising a compressed microtablet that is coated with a water-retardant polymer. Additional aspects of the present invention are directed to an oral dosage form comprising an opioid agonist and at least one compressed microtablet coated with a water retardant polymer. The compressed microtablet may comprise an opioid antagonist.
摘要翻译：本发明的方面涉及耐药性口服剂型，其包含用阻燃性聚合物涂覆的压缩微片。本发明的另外的方面涉及包含阿片样物质激动剂和涂覆有阻燃聚合物的至少一个压缩微片的口服剂型。压缩的微片可以包含阿片样物质拮抗剂。

2. 发明申请

US20080299189A1 CONTROLLED RELEASE DOPAMINE AGONIST COMPOSITIONS 审中-公开
标题翻译：受控释放多巴胺激动剂组合物
公开(公告)号：US20080299189A1
公开(公告)日：2008-12-04
申请号：US12126575
申请日：2008-05-23
申请人： Jonathan David Bortz , Michael Grimshaw , David F. Erkoboni
发明人： Jonathan David Bortz , Michael Grimshaw , David F. Erkoboni
IPC分类号： A61K9/52 , A61K9/24 , A61K31/428 , A61P25/16
CPC分类号： A61K31/428 , A61K9/2077 , A61K9/209 , A61K9/5084
摘要： The present invention relates to a multiphase release oral pharmaceutical formulation having a dopamine agonist as an active ingredient. The multiphase composition comprises at least two different release components. The invention relates to controlled release pharmaceutical compositions of pramipexole or a pharmaceutically acceptable salt thereof for once-daily administration.
摘要翻译：本发明涉及具有多巴胺激动剂作为活性成分的多相释放口服药物制剂。多相组合物包含至少两种不同的释放组分。本发明涉及普拉克索的控释药物组合物或其药学上可接受的盐，用于每日一次给药。

3. 发明授权

US09056054B2 Abuse resistant oral dosage forms 有权
标题翻译：滥用耐药性口服剂型
公开(公告)号：US09056054B2
公开(公告)日：2015-06-16
申请号：US13379481
申请日：2010-06-25
申请人： Christopher C. Dick , David F. Erkoboni , Charanjit R. Behl , Gary Bubb
发明人： Christopher C. Dick , David F. Erkoboni , Charanjit R. Behl , Gary Bubb
IPC分类号： A61K9/28 , A61K9/20 , A61K31/485
CPC分类号： A61K9/28 , A61K9/2027 , A61K9/2095 , A61K9/2846 , A61K9/2866 , A61K9/2873 , A61K9/2893 , A61K31/485
摘要： Aspects of the present invention are directed to abuse resistant oral dosage forms comprising a compressed microtablet that is coated with a water-retardant polymer. Additional aspects of the present invention are directed to an oral dosage form comprising an opioid agonist and at least one compressed microtablet coated with a water retardant polymer. The compressed microtablet may comprise an opioid antagonist.
摘要翻译：本发明的方面涉及耐药性口服剂型，其包含用阻燃性聚合物涂覆的压缩微片。本发明的另外的方面涉及包含阿片样物质激动剂和涂覆有阻燃聚合物的至少一个压缩微片的口服剂型。压缩的微片可以包含阿片样物质拮抗剂。

4. 发明申请

US20080292695A1 CARVEDILOL FORMS, COMPOSITIONS, AND METHODS OF PREPARATION THEREOF 审中-公开
标题翻译：卡维地洛形式，组合物及其制备方法
公开(公告)号：US20080292695A1
公开(公告)日：2008-11-27
申请号：US11949158
申请日：2007-12-03
申请人： Kristin Arnold , E. Brendan Magrab , David F. Erkoboni , Zhongshui Yu , Siva Rama K. Nutalapati , Rakeshkumar K. Lad
发明人： Kristin Arnold , E. Brendan Magrab , David F. Erkoboni , Zhongshui Yu , Siva Rama K. Nutalapati , Rakeshkumar K. Lad
IPC分类号： A61K31/403 , A61K9/52 , A61K9/28 , A61P9/00
CPC分类号： A61K9/1605 , A61K9/28 , A61K9/50
摘要： Disclosed are amorphous carvedilol salt forms, controlled-release carvedilol compositions, and methods of preparing the forms and compositions.
摘要翻译：公开了无定形卡维地洛盐形式，控释卡维地洛组合物以及制备形式和组合物的方法。

5. 发明授权

US06379707B2 Method of making granular pharmaceutical vehicle 失效
标题翻译：制造颗粒药物载体的方法
公开(公告)号：US06379707B2
公开(公告)日：2002-04-30
申请号：US09886100
申请日：2001-06-21
申请人： Ronald S. Vladyka, Jr. , David F. Erkoboni , Pamela R. Stergios
发明人： Ronald S. Vladyka, Jr. , David F. Erkoboni , Pamela R. Stergios
IPC分类号： A61K916
CPC分类号： A61K9/145 , A61K9/1617 , A61K9/1652 , A61K31/496 , C07D231/12 , C07D233/56 , C07D249/08
摘要： A formulation of a sparingly water-soluble, crystalline pharmaceutically active agent wherein the active agent is converted to and stabilized in its amorphous form as a solid solution of a normally hydrophobic vehicle is described. The amorphous state is stabilized by the composition of the formulation, providing long shelf life of the improved composition. This stabilized formulation also provides increased solubility and bioavailability of the active agent. Solutions of the active agent are stabilized by the composition, preventing recrystallization and precipitation of the less soluble, crystalline form of the active agent from aqueous solutions thereof.
摘要翻译：描述了一种微溶于水的结晶药物活性剂的制剂，其中活性剂以正常疏水性载体的固体溶液转化为其非晶形式并稳定化。无定形状态通过制剂的组成稳定，提供改进的组合物的长的保质期。这种稳定化的制剂还提供活性剂的增加的溶解度和生物利用度。活性剂的溶液通过组合物稳定，防止活性剂从其水溶液中的较不溶解的结晶形式的再结晶和沉淀。

6. 发明申请

US20080139655A1 SUSTAINED-RELEASE COMPOSITION AND METHOD OF USE THEREOF 审中-公开
标题翻译：持续释放组合物及其使用方法
公开(公告)号：US20080139655A1
公开(公告)日：2008-06-12
申请号：US11850063
申请日：2007-09-05
申请人： Jonathan Bortz , Michael Grimshaw , David F. Erkoboni , Michael F. Dickus
发明人： Jonathan Bortz , Michael Grimshaw , David F. Erkoboni , Michael F. Dickus
IPC分类号： A61K31/195 , A61P25/28
CPC分类号： A61K31/198 , A61K9/0065 , A61K9/205 , A61K9/2054
摘要： A pharmaceutical composition comprising levodopa is provided that, when administered in a unit dosage amount of levodopa of about 100 to about 500 mg at a dosage interval of about 6 to about 24 hours, exhibits a sufficiently long release period and a sufficiently long residence time in the upper gastrointestinal tract to provide a trough concentration of levodopa in plasma of the subject that is not lower than a minimum threshold concentration below which adverse motor effects are observed in the subject. A method for treating Parkinson's disease in a subject is also provided, comprising orally administering such a composition to the subject in a unit dosage amount of levodopa of about 50 to about 1000 mg at a dosage interval of about 3 to about 24 hours.
摘要翻译：提供包含左旋多巴的药物组合物，其以约6至约24小时的剂量间隔以约100至约500mg的单位剂量的左旋多巴施用时，显示足够长的释放期和足够长的停留时间上消化道提供受试者血浆中左旋多巴的谷浓度，其不低于在受试者中观察到不良运动效应的最低阈值浓度。还提供了治疗受试者中帕金森病的方法，其包括以约3至约24小时的剂量间隔以约50至约1000mg的单位剂量的左旋多巴口服施用该组合物。

7. 发明授权

US06596312B1 Hydrolyzed cellulose granulations of salts of drugs 失效
标题翻译：药物盐水解纤维素颗粒
公开(公告)号：US06596312B1
公开(公告)日：2003-07-22
申请号：US09669533
申请日：2000-09-26
申请人： David F. Erkoboni , Ronald S. Vladyka, Jr. , Christopher A. Sweriduk , Andrew J. Favara
发明人： David F. Erkoboni , Ronald S. Vladyka, Jr. , Christopher A. Sweriduk , Andrew J. Favara
IPC分类号： A61K920
CPC分类号： A61K9/1652 , A61K9/2054
摘要： The present invention provides a method for preparing a spray-dried, compressible granular formulation for preparing pharmaceutical tablets in which essentially water-insoluble, acidic, amphoteric, and basic pharmaceutically active agents are converted to more water-soluble salts which are granulated with hydrolyzed cellulose, drug-containing slurries, the resulting granulations, capsules containing granulations, and pharmaceutical tablets compressed from such granules. In these formulations there is employed from 1% to 85% by weight of the pharmaceutically active agent and its salt form, from 5% to 99% of hydrolyzed cellulose, based on the dry weight of the granulation, and optionally, conventional granulation and/or tableting additives such as surfactants, disintegrants, and antiadherents/flow aids. Said tablets have significantly increased dissolution of the pharmaceutically active agent at the pH of the gastrointestinal tract in comparison with the unconverted free pharmaceutically active agent.
摘要翻译：本发明提供了一种制备用于制备药物片剂的喷雾干燥的可压缩颗粒制剂的方法，其中基本上不溶于水的，酸性的，两性的和碱性的药物活性剂转化为更多的水溶性盐，其被水解的纤维素，含药浆液，所得颗粒，含有颗粒的胶囊和从该颗粒压制的药物片剂。在这些制剂中，基于造粒物的干重，使用1％至85％重量的药学活性剂及其盐形式，5％至99％的水解纤维素，以及任选的常规制粒和/ 或压片添加剂如表面活性剂，崩解剂和抗粘附剂/流动助剂。与未转化的游离药物活性剂相比，所述片剂在胃肠道的pH下显着增加药物活性剂的溶出度。

8. 发明授权

US5725886A Microcrystalline cellulose spheronization composition 失效
标题翻译：微晶纤维素滚圆组合物
公开(公告)号：US5725886A
公开(公告)日：1998-03-10
申请号：US311800
申请日：1994-09-26
申请人： David F. Erkoboni , Scott A. Fiore , Thomas A. Wheatley
发明人： David F. Erkoboni , Scott A. Fiore , Thomas A. Wheatley
IPC分类号： A61K9/14 , A61K9/16 , A61K47/40 , C08J3/00 , C08L1/00 , C08L1/02 , C08L1/08 , C08L1/28
CPC分类号： C08J3/005 , A61K9/1652 , C08L1/02 , C08J2300/14 , C08J2301/00 , C08L1/28
摘要： A particulate co-processed unattrited microcrystalline cellulose:hydrocolloid composition wherein the respective components are present in a weight ratio of from about 99:1 to 70:30. The composition is useful as a spheronizing agent for producing spheroids of uniform size and sphericity and having high drug loadings. The composition is produced by drying a slurry of the microcrystalline cellulose in an aqueous solution of the hydrocolloid. The preferred hydrocolloid is methylcellulose.
摘要翻译：一种颗粒状协同处理的未结晶微晶纤维素：水胶体组合物，其中各组分以约99:1至70:30的重量比存在。该组合物可用作生产具有均匀尺寸和球形度并且具有高药物负载量的球状体的球形化剂。通过将微晶纤维素的浆液干燥在水胶体的水溶液中来制备组合物。优选的水胶体是甲基纤维素。

9. 发明申请

US20090263478A1 CARVEDILOL FORMS, COMPOSITIONS, AND METHODS OF PREPARATION THEREOF 审中-公开
公开(公告)号：US20090263478A1
公开(公告)日：2009-10-22
申请号：US12500199
申请日：2009-07-09
申请人： Kristin Arnold , David F. Erkoboni , Rakeshkumar K. Lad , Siva Rama K. Nutalapati , Zhongshui Yu
发明人： Kristin Arnold , David F. Erkoboni , Rakeshkumar K. Lad , Siva Rama K. Nutalapati , Zhongshui Yu
IPC分类号： A61K9/58 , A61K31/403
CPC分类号： A61K9/1605 , A61K9/28 , A61K9/50
摘要： Disclosed are amorphous carvedilol salt forms, controlled-release carvedilol compositions, and methods of preparing the forms and compositions.

10. 发明授权

US06858725B1 Microcrystalline cellulose cushioning granules 失效
标题翻译：微晶纤维素缓冲颗粒
公开(公告)号：US06858725B1
公开(公告)日：2005-02-22
申请号：US09708581
申请日：2000-11-09
申请人： Ronald S. Vladyka, Jr. , David F. Erkoboni , Christopher A. Sweriduk
发明人： Ronald S. Vladyka, Jr. , David F. Erkoboni , Christopher A. Sweriduk
IPC分类号： A61K9/20 , A61K31/715 , C07H1/00 , C08J3/12 , C08B37/00 , A61K9/16
CPC分类号： C08J3/12 , A61K9/2054 , A61K31/715 , C07H1/00 , C08J2301/02
摘要： Granulation of microcrystalline cellulose with a granulating fluid consisting of water and a water-miscible, volatile, polar organic solvent yields porous granules which are comprised of particles that are larger than the ungranulated microcrystalline cellulose. This granulated microcrystalline cellulose is capable of cushioning controlled release particles and barrier coated particles from the compression forces used in tableting, thereby maintaining the physical integrity of the components of the tablet.
摘要翻译：使用由水和水混溶性挥发性极性有机溶剂组成的造粒流体对微晶纤维素进行造粒产生的多孔颗粒由大于无微晶纤维素的颗粒组成。该颗粒状微晶纤维素能够从压片中使用的压缩力缓冲控制释放颗粒和阻隔涂层颗粒，从而保持片剂组分的物理完整性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式